In the last trading session, 1.29 million shares of the Apogee Therapeutics Inc (NASDAQ:APGE) were traded, and its beta was 1.87. Most recently the company’s share price was $39.89, and it changed around -$0.95 or -2.33% from the last close, which brings the market valuation of the company to $2.37B. APGE currently trades at a discount to its 52-week high of $70.56, offering almost -76.89% off that amount. The share price’s 52-week low was $29.10, which indicates that the current value has risen by an impressive 27.05% since then. We note from Apogee Therapeutics Inc’s average daily trading volume that its 10-day average is 0.76 million shares, with the 3-month average coming to 602.48K.
Apogee Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 9 analysts rate the stock as a Sell; another 0 rate it as Overweight. Among the rest, 0 recommended APGE as a Hold, whereas 9 deemed it a Buy, and 0 rated it as Underweight. Apogee Therapeutics Inc is expected to report earnings per share of -1.19 for the current quarter.
Apogee Therapeutics Inc (NASDAQ:APGE) trade information
Instantly APGE has showed a red trend with a performance of -2.33% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 41.38 on recent trading dayincreased the stock’s daily price by 3.6%. The company’s shares are currently down -11.94% year-to-date, but still up 2.73% over the last five days. On the other hand, Apogee Therapeutics Inc (NASDAQ:APGE) is 19.54% up in the 30-day period. We can see from the shorts that 8.16 million shares have been sold at a short interest cover period of 10.72 day(s).
The consensus price target as assigned by Wall Street analysts is $95, which translates to bulls needing to increase their stock price by 58.01% from its current value. Analyst projections state that APGE is forecast to be at a low of $95 and a high of $95.
Forecasts for the next quarter put sales growth at 0.00%.
Apogee Therapeutics Inc earnings are expected to increase by -56.75% in 2025, but the outlook is negative -22.96% per year for the next five years.
APGE Dividends
Apogee Therapeutics Inc’s next quarterly earnings report is expected to be released on 2025-Mar-02.
Apogee Therapeutics Inc (NASDAQ:APGE)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 11.36% of Apogee Therapeutics Inc shares, and 130.16% of them are in the hands of institutional investors. The stock currently has a share float of 146.85%. Apogee Therapeutics Inc stock is held by 232.0 institutions, with VR ADVISER, LLC being the largest institutional investor. By 2024-06-30, it held 15.0284% of the shares, which is about 8.49 million shares worth $334.21 million.
WELLINGTON MANAGEMENT GROUP LLP, with 6.2761% or 3.55 million shares worth $139.57 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Vanguard Health Care Fund and Fidelity Growth Company Fund were the top two Mutual Funds as of Oct 31, 2024 . The former held 2.0 shares worth $79.78 million, making up 4.44% of all outstanding shares. On the other hand, Fidelity Growth Company Fund held roughly 1.41 shares worth around $56.1 million, which represents about 3.12% of the total shares outstanding.
